Condition: Myasthaenia Gravis · Sponsor: Clinique Neuro-Outaouais
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
This description comes directly from the study's public registry record.
François Jacques, Doctor · 819-777-2500 · francois.jacques@neuro-outaouais.ca
Victorine Sikati Foko, Nurse · 8197772500
Always discuss trial participation with your own doctor first.
| Clinique Neuro-Outaouais | Gatineau, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06765161